AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fagron N.V.

Pre-Annual General Meeting Information Apr 11, 2025

3949_rns_2025-04-11_3e806515-4563-4b23-a4bd-a263f722895b.pdf

Pre-Annual General Meeting Information

Open in Viewer

Opens in native device viewer

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2025 – 8 AM CET

Fagron publishes agenda for 2025 annual shareholders meeting

The Board of Directors of Fagron NV invites shareholders to attend Fagron's annual general meeting of shareholders on Monday 12 May 2025.

Agenda

The agenda includes the discussion of the annual report, the approval of the annual financial statements and the dividend proposal of €0.35 for the financial year 2024, and the approval of the remuneration policy. The full agenda and further details can be found in the meeting documents.

Meeting and meeting documents

Fagron's annual general meeting of shareholders will be held at its statutory seat, Venecoweg 20A, 9810, Nazareth (Belgium) and by audio and video conference on Monday 12 May 2025 at 3PM CET. The convocation, including the agenda, and other documents related to this general meeting of shareholders can be found on the Fagron website.

Further information

Ignacio Artola Global Investor Relations Leader Tel. +34 670 385 795 [email protected]

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 30 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR'. Fagron's operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Talk to a Data Expert

Have a question? We'll get back to you promptly.